Leadership

Moonwalk Biosciences has closed a $70 million Series B to advance its adipose-targeted RNAi platform toward first-in-human studies.

The Trump administration adds nine midsize pharmaceutical companies, including Teva, UCB, Astellas, and BeOne Medicines to its Most-Favored-Nation drug pricing program.

This year's Pharm Exec Emerging Pharma Leaders represent a new and growing breed of leader: Those capable of navigating an industry where scientific advances, technology and business models are evolving simultaneously.

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for FDA commissioner.

From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.

Christopher Savage, managing director, Propensity4, and chief of staff, Inizio Engage, on creating lasting impact over chasing the next opportunity.

Abid Rahman, head of AI Agency and innovation at EVERSANA, explains how the pharmaceutical industry is moving from generative to agentic AI.

Sarah Ghosh, U.S. scientific marketing lead in oncology at Regeneron, discusses developing and adapting the narrative for a medication for every global market.

Rena Denoncourt, chief operating officer at Corsera Health, discusses the operational challenges of building a startup and how she balances prioritization with the flexibility drug development demands.

Dr. Nick Botwood, chief medical officer and head of research and development at Syndax Pharmaceuticals, draws on his career to explain what separates good R&D organizations from great ones.

A career Q&A with Professor Patrick T. Harker, B.S., M.S., Ph.D., of the Wharton School of the University of Pennsylvania.

Ken Banta and Craig Tooman on why the best leaders win by asking better questions — not just chasing more data — and what that means for drug development, funding and AI in the years ahead.

Abu Dhabi is expanding its role in global biopharmaceutical manufacturing through strategic investments, advanced infrastructure, and international partnerships designed to accelerate biologics production, innovation, and supply chain resilience.

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of concentrated AI bets — not scattered pilots — can better drive real transformation without losing sight of governance, culture or patients.

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 billion patent cliff, the pricing pressures of the Inflation Reduction Act, and shifting regulatory dynamics.

Jeff Talbot of Roseman University of Health Sciences discusses how Las Vegas is positioning itself as a growing life sciences hub by offering cost-effective laboratory space, access to capital, and a flexible environment for biotech startups and emerging companies.

As the executive insights in our June issue illustrate, breakthroughs in pharma are rarely the result of a single discovery but are the product of organizations — and people — designed to keep moving forward.

Fresh off the HBA's Honorable Mentor award, Rick Winningham, CEO of Theravance Biopharma, reflects on a career defined by cultivating the cultures driving the science.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

David Coman, CEO, BGBx, explains how the firm's rebranding reflects a broader shift in biopharma commercialization, where integrating consulting, communications, and a three-dimensional science framework is increasingly necessary for companies.

Drawing on nearly two decades in biotech finance,Troy Ignelzi outlines why operational discipline, strategic storytelling, and long-term conviction have become essential survival tools in an increasingly unforgiving life sciences market.

Toragen CEO Sandra Coufal, MD, discusses why the company is targeting HPV’s overlooked E5 protein, positioning its small-molecule therapy as a potential complement to checkpoint inhibitors like Keytruda across HPV-driven cancers.

FDA undergoes leadership upheaval, leaving key drug and biologics divisions under interim control and raising concerns over regulatory continuity amid turnover at the agency’s highest levels.

BeOne Medicines’ John Oyler on building an oncology pharma power from a disruptive idea — and playing the long game on speed, science and scale.

At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares.